Cereno Scientific reaches its largest milestone to date

27 September, 2019

Cereno Scientific is in full swing preparing its Phase II study with the drug candidate CS1, aiming to initiate the study in the first half of 2020. Yesterday, the company received study approval from the regulatory authorities in Russia. The company has thus achieved its largest milestone to date. Next up is study approval in Bulgaria as well as to complete both upscaling and production of clinical trial material before the study can be initiated.

Read the full article on BioStock here.